Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Moderna, Inc.

MRNANASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 7, 2026Accepted Aug 7, 2026, 4:11 PM EDTFiling CIK 1682852Accession 0001682852-26-000153
Share

Structured filing — 4

form4.xml

Open full document ↗

Filing details

Report period
2026-08-05
Issuer
Moderna, Inc.
Issuer CIK
0001682852
Trading symbol
MRNA
Rule 10b5-1 indication
Checked

Reporting owner 1

Name
Bancel Stephane
Reporting owner CIK
0001443340
Relationship
Director · Officer
Officer title
Chief Executive Officer
Address
C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE, MA, 02142

Non-derivative transactions

Non-derivative transactions · 6 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-08-05M · Form 4[F1]499,246A19.156,687,037D
Common Stock2026-08-05S · Form 4[F1]147,473D56.21[F2]6,539,564D
Common Stock2026-08-05S · Form 4[F1]124,838D56.96[F3]6,414,726D
Common Stock2026-08-05S · Form 4[F1]39,891D58.12[F4]6,374,835D
Common Stock2026-08-05S · Form 4[F1]187,044D58.79[F5]6,187,791D
Common Stock2026-08-06M · Form 4[F1]252,469A19.156,440,260D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Non-derivative holdings

Non-derivative holdings · 2 reported rows
SecurityAmount ownedOwnershipNature of ownership
Common Stock9,210,686ISee Footnote[F6]
Common Stock6,564,880ISee Footnote[F7]
Table key
I
Indirect

Derivative transactions

Derivative transactions · 4 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)19.152026-08-05M · Form 4[F1]370,853D0[F8]2026-08-10Common Stock370,853187,541D
Stock Option (Right to Buy)19.152026-08-05M · Form 4[F1]128,393D0[F8]2026-08-10Common Stock128,39364,928D
Stock Option (Right to Buy)19.152026-08-06M · Form 4[F1]187,541D0[F8]2026-08-10Common Stock187,5410D
Stock Option (Right to Buy)19.152026-08-06M · Form 4[F1]64,928D0[F8]2026-08-10Common Stock64,9280D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Footnotes

F1
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
F6
These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.↩ 1
F7
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.↩ 1
F8
This option is fully vested and exercisable.↩ 1↩ 2↩ 3↩ 4

Signature 1

Signed
/s/ James Dillon, as Attorney-in-Fact
Date
2026-08-07

Company context

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Current securities

Recent company filings

  1. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementNov 16, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 13, 2026
  3. 10-Q filingNov 6, 2026
  4. Results of Operations and Financial ConditionNov 6, 2026
  5. SCHEDULE 13G/A - filed by FMR LLC regarding Moderna, Inc.Nov 5, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.